SUPPORTING INFECTIOUS DISEASE RESEARCH

## Mycobacterium tuberculosis, Strain 96-2661

#### Catalog No. NR-30929

This reagent is the tangible property of the U.S. Government.

**Product Description:** *Mycobacterium tuberculosis (M. tuberculosis)*, strain 96-2661 was isolated between 1995 and 2000 from human sputum from an HIV-positive patient infected with pulmonary tuberculosis in North America.

## Lot<sup>1</sup>: 70005365

# Manufacturing Date: 07JUL2017

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis <sup>2</sup>		
Cellular morphology	Gram-positive rods	Gram-positive rods
Colony morphology <sup>3</sup>	Report results	Irregular, slight peaked, undulate, rough and cream (Figure 1)
Growth rate	≥ 7 days	20 days
Growth at 26°C	Negative	Negative
Growth at 37°C	Positive	Positive
Acid-fast stain	Positive (red colonies)	Positive (red colonies)
Pigmentation in the dark (Scotochromogen)	Negative (no pigment)	Negative (no pigment)
Photoinduction for 1 hour (Photochromogen)	Negative (no pigment)	Negative (no pigment)
Nonchromogen (no pigment)	Positive (no pigment)	Positive (no pigment)
Biochemical tests		
Niacin production <sup>4</sup>	Positive	Positive
Nitrate reduction	Positive	Positive
Pyrazinamidase	Positive	Positive
Antibiotic Susceptibility Profile		
Sensititre <sup>™</sup> System <sup>5,6</sup>		
Amikacin	Report results	0.25 μg/mL
Cycloserine	Report results	8 μg/mL <sup>7,8</sup>
Ethambutol	Report results	1 µg/mL <sup>9</sup>
Ethionamide	Report results	2.5 µg/mL <sup>8-10</sup>
Isoniazid	Report results	≤ 0.03 µg/mL
Kanamycin	Report results	2.5 μg/mL <sup>8,11</sup>
Moxifloxacin	Report results	0.25 μg/mL
Ofloxacin	Report results	1 µg/mL
Para-aminosalicylic acid	Report results	≤ 0.5 µg/mL <sup>9</sup>
Rifabutin	Report results	≤ 0.12 µg/mL <sup>9</sup>
Rifampin	Report results	≤ 0.12 µg/mL
Streptomycin	Report results	0.5 μg/mL <sup>9</sup>
Genotypic Analysis		
Sequencing of Heat Shock Protein 65 gene	≥ 99% sequence identity to	100% sequence identity to
(~ 440 base pairs)	M. tuberculosis type strain	M. tuberculosis type strain
	(GenBank: AL123456)	(GenBank: AL123456) <sup>12</sup>
Purity (post-freeze)		
Middlebrook 7H10 agar with OADC enrichment <sup>13</sup>	Growth consistent with expected	Growth consistent with expected
	colony morphology	colony morphology
Tryptic Soy agar <sup>14</sup>	Report results	Growth consistent with expected
		colony morphology
Viability (post-freeze) <sup>3</sup>	Growth	Growth

<sup>1</sup>NR-30929 was produced by inoculation of the deposited material into Middlebrook 7H9 broth with ADC enrichment. Broth inoculum was added to Middlebrook 7H10 agar with OADC enrichment kolles, which were grown for 32 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> to produce this lot.

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **DICIÍ** RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

<sup>2</sup>Information on Mycobacterium testing is available from Ribón, W. "Biochemical Isolation and Identification of Mycobacteria." <u>Biochemical Testing</u>. (2012) Jose C. Jimenez-Lopez (Ed.), InTech, <u>http://www.intechopen.com/books/biochemical-testing/biochemical-isolation-and-identification-of-mycobacteria</u> and Lévy-Frébault, V. V. and F. Portaels. "Proposed Minimal Standards for the Genus *Mycobacterium* and for Description of New Slowly Growing *Mycobacterium* Species." <u>Int. J. Syst. Bacteriol.</u> 42 (1992): 315-323. PubMed: 1581193.

<sup>3</sup>20 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Middlebrook 7H10 agar with OADC enrichment

<sup>4</sup>All mycobacteria produce niacin but only *M. tuberculosis* accumulates it, resulting in a positive test for *M. tuberculosis*.

<sup>5</sup>Sensititre<sup>TM</sup> System *Mycobacterium tuberculosis* MIC Plate, Thermo Scientific<sup>TM</sup>, catalog number MYCOTB

<sup>6</sup>Minimum Inhibitory Concentration (MIC); No Clinical & Laboratory Standards Institute (CLSI) interpretations of the Sensititre™ System data for *M. tuberculosis* are currently available.

<sup>7</sup>Two MICs were observed for cycloserine (4 µg/mL and 8 µg/mL) under identical test conditions. The highest MIC is being reported as the test result.
<sup>8</sup>Variability in the MIC result by the Sensititre™ method has been demonstrated (Lee, J., et al. "Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs." <u>Antimicrob. Agents Chemother.</u> 58 (2014):


11-18. PubMed: 24100497.), with the results for a single antibiotic typically within one doubling dilution. <sup>9</sup>For streptomycin, ethionamide, para-aminosalicylic acid, rifabutin and ethambutol, the endpoint for these drugs is determined by the well with

- approximately 80% inhibition of growth compared to the positive control well with no drug. <sup>10</sup>Two MICs were observed for ethionamide (1.2 µg/mL and 2.5 µg/mL) under identical test conditions. The highest MIC is being reported as the test result.
- <sup>11</sup>Two MICs were observed for kanamycin (1.2 µg/mL and 2.5 µg/mL) under identical test conditions. The highest MIC is being reported as the test result

<sup>12</sup>Also consistent with *M. africanum*, *M. bovis*, *M. canettii*, *M. caprae* and *M. microti* 

<sup>13</sup>Purity of this lot was assessed for 40 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.

<sup>14</sup>Purity of this lot was assessed for 20 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.



#### /Heather Couch/ Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



29 NOV 2018